Kymera Therapeutics KYMR
NASDAQ KYMR
$107.39 -2.73 (-2.48%)
At close: Oct 2, 2026 · 4:00 PM EDT

Kymera Therapeutics (KYMR) Depreciation & Amortization (CF) (2019 - 2026)

Updated

Kymera Therapeutics (KYMR) posted Depreciation & Amortization (CF) of $2.03 million for Q2 2026, down 2.6% from $2.08 million a year earlier but up 0.4% from the prior quarter.

Analysis

Kymera Therapeutics (KYMR) Depreciation & Amortization (CF) (2019 - 2026) Analysis & Trends

For the trailing twelve months through Jun 30, 2026, Depreciation & Amortization (CF) at Kymera Therapeutics was $8.23 million, up 1.6% year-over-year; for FY2025, it came in at $8.31 million, up 12.7% from FY2024.

  • Annual Depreciation & Amortization (CF) has increased for six consecutive years, with a five-year compound annual growth rate of 36.4% (FY2020 to FY2025).
  • In prior years, Kymera Therapeutics' Depreciation & Amortization (CF) was $7.37 million in FY2024 (+106.8%), $3.57 million in FY2023 (+19.8%), $2.98 million in FY2022 (+24.2%) and $2.4 million in FY2021 (+36.0%).
  • Quarterly Depreciation & Amortization (CF) has run from a low of $671,000 in Q3 2021 to a high of $2.15 million in Q3 2025 over five years.
  • On a year-over-year basis, Depreciation & Amortization (CF) increased in six of the last eight quarters, with growth averaging 37.4%.
  • The strongest year-over-year quarter for Depreciation & Amortization (CF) in the past five years was Q4 2024, with growth of 123.0%; the weakest was Q2 2026, with a decline of 2.6%.
  • According to Business Quant data, Depreciation & Amortization (CF) for the three prior quarters was $2.02 million (Q1 2026), $2.03 million (Q4 2025) and $2.15 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Dep. & Amort. (Qtr)
1 Eli Lilly 1,082.65 Bn 1,051.23 Bn 19.71 Bn 534.00 Mn
2 Johnson & Johnson 623.68 Bn 542.21 Bn 17.26 Bn 1.96 Bn
3 AbbVie 459.43 Bn 432.59 Bn 12.70 Bn 194.00 Mn
4 Merck 354.80 Bn 309.23 Bn 12.21 Bn 599.00 Mn
5 Novartis Ag 269.16 Bn 225.03 Bn 11.24 Bn -
6 Astrazeneca 244.40 Bn 217.97 Bn 12.86 Bn 1.93 Bn
7 Amgen 220.17 Bn 175.57 Bn 7.24 Bn 1.11 Bn
8 Gilead Sciences 183.05 Bn 157.16 Bn 6.22 Bn 98.00 Mn
9 Pfizer 160.27 Bn 107.22 Bn 10.94 Bn 1.62 Bn
10 Kymera Therapeutics 9.12 Bn 6.42 Bn - 2.03 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 2.03 Mn
Mar 31, 2026 2.02 Mn
Dec 31, 2025 2.03 Mn
Sep 30, 2025 2.15 Mn
Jun 30, 2025 2.08 Mn
Mar 31, 2025 2.05 Mn
Dec 31, 2024 1.99 Mn
Sep 30, 2024 1.99 Mn
Jun 30, 2024 1.94 Mn
Mar 31, 2024 1.46 Mn
Dec 31, 2023 891,000.00
Sep 30, 2023 895,000.00
Jun 30, 2023 900,000.00
Mar 31, 2023 879,000.00
Dec 31, 2022 818,000.00
Sep 30, 2022 767,000.00
Jun 30, 2022 705,000.00
Mar 31, 2022 687,000.00
Dec 31, 2021 689,000.00
Sep 30, 2021 671,000.00
API Access

Kymera Therapeutics Depreciation & Amortization (CF) API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=depreciation-and-amortization-cf&ticker=KYMR&period=max&api_key=YOUR_API_KEY